319 related articles for article (PubMed ID: 31383252)
1. LRRK2 and membrane trafficking: nexus of Parkinson's disease.
Hur EM; Jang EH; Jeong GR; Lee BD
BMB Rep; 2019 Sep; 52(9):533-539. PubMed ID: 31383252
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
[TBL] [Abstract][Full Text] [Related]
3. The LRRK2 N-terminal domain influences vesicle trafficking: impact of the E193K variant.
Marku A; Carrion MDP; Pischedda F; Marte A; Casiraghi Z; Marciani P; von Zweydorf F; Gloeckner CJ; Onofri F; Perego C; Piccoli G
Sci Rep; 2020 Mar; 10(1):3799. PubMed ID: 32123243
[TBL] [Abstract][Full Text] [Related]
4. LRRK2 at the pre-synaptic site: A 16-years perspective.
Pischedda F; Piccoli G
J Neurochem; 2021 Apr; 157(2):297-311. PubMed ID: 33206398
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 and the Endolysosomal System in Parkinson's Disease.
Erb ML; Moore DJ
J Parkinsons Dis; 2020; 10(4):1271-1291. PubMed ID: 33044192
[TBL] [Abstract][Full Text] [Related]
6. Leucine-rich repeat kinase 2 and Parkinson's disease.
Kang UB; Marto JA
Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
[TBL] [Abstract][Full Text] [Related]
7. Role of LRRK2 in the regulation of dopamine receptor trafficking.
Rassu M; Del Giudice MG; Sanna S; Taymans JM; Morari M; Brugnoli A; Frassineti M; Masala A; Esposito S; Galioto M; Valle C; Carri MT; Biosa A; Greggio E; Crosio C; Iaccarino C
PLoS One; 2017; 12(6):e0179082. PubMed ID: 28582422
[TBL] [Abstract][Full Text] [Related]
8. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
Chen J; Chen Y; Pu J
Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
[TBL] [Abstract][Full Text] [Related]
9. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila.
Inoshita T; Arano T; Hosaka Y; Meng H; Umezaki Y; Kosugi S; Morimoto T; Koike M; Chang HY; Imai Y; Hattori N
Hum Mol Genet; 2017 Aug; 26(15):2933-2948. PubMed ID: 28482024
[TBL] [Abstract][Full Text] [Related]
10. Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis.
Heaton GR; Landeck N; Mamais A; Nalls MA; Nixon-Abell J; Kumaran R; Beilina A; Pellegrini L; Li Y; ; Harvey K; Cookson MR
Neurobiol Dis; 2020 Jul; 141():104948. PubMed ID: 32434048
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 and Rab GTPases.
Pfeffer SR
Biochem Soc Trans; 2018 Dec; 46(6):1707-1712. PubMed ID: 30467121
[TBL] [Abstract][Full Text] [Related]
12. The Parkinson's Disease Protein LRRK2 Interacts with the GARP Complex to Promote Retrograde Transport to the trans-Golgi Network.
Beilina A; Bonet-Ponce L; Kumaran R; Kordich JJ; Ishida M; Mamais A; Kaganovich A; Saez-Atienzar S; Gershlick DC; Roosen DA; Pellegrini L; Malkov V; Fell MJ; Harvey K; Bonifacino JS; Moore DJ; Cookson MR
Cell Rep; 2020 May; 31(5):107614. PubMed ID: 32375042
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 and vesicle trafficking.
Sanna G; Del Giudice MG; Crosio C; Iaccarino C
Biochem Soc Trans; 2012 Oct; 40(5):1117-22. PubMed ID: 22988875
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 at the interface of autophagosomes, endosomes and lysosomes.
Roosen DA; Cookson MR
Mol Neurodegener; 2016 Dec; 11(1):73. PubMed ID: 27927216
[TBL] [Abstract][Full Text] [Related]
15. Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson's disease.
Cookson MR
Biochem Soc Trans; 2016 Dec; 44(6):1603-1610. PubMed ID: 27913668
[TBL] [Abstract][Full Text] [Related]
16. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype.
Rassu M; Biosa A; Galioto M; Fais M; Sini P; Greggio E; Piccoli G; Crosio C; Iaccarino C
J Cell Mol Med; 2019 Dec; 23(12):8505-8510. PubMed ID: 31560168
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity.
Gómez-Suaga P; Rivero-Ríos P; Fdez E; Blanca Ramírez M; Ferrer I; Aiastui A; López De Munain A; Hilfiker S
Hum Mol Genet; 2014 Dec; 23(25):6779-96. PubMed ID: 25080504
[TBL] [Abstract][Full Text] [Related]
18. Caught in the act: LRRK2 in exosomes.
Wang S; West AB
Biochem Soc Trans; 2019 Apr; 47(2):663-670. PubMed ID: 30837321
[TBL] [Abstract][Full Text] [Related]
19. The Cell Biology of LRRK2 in Parkinson's Disease.
Usmani A; Shavarebi F; Hiniker A
Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33526455
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 links genetic and sporadic Parkinson's disease.
Kluss JH; Mamais A; Cookson MR
Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
